FBFatemah Baron

Fatemah Baron

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Fatemah Baron has a total of 48 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Clinical and treatment characteristics of axial spondyloarthritis in Kuwait: a registry-based cross-sectional study

    by Mohammad Khudadah, Ghaydaa Aldabie, Kholoud Saleh, Wesam Gouda, Dalal Alkhudair, Fatemah Baron, Amjad Alkadi, Fatemah Abutiban, Ramia Alhasan, Aqeel Ghanem, et al.

  • Open Access

    Arab League of Associations for Rheumatology (ArLAR)

    by Fatemah Abutiban, Hebah AlHajeri, Amjad Alkadi, Fatemah Baroun

    The Arab League of Associations for Rheumatology (ArLAR) was established in 1995 to strengthen the relations between rheumatologists in the Arab countries. The main aims of this league were to keep abreast of global medical developments, promote health awareness among Arabs, and play a significant role in the global scientific movement. It was necessary to establish such a regional Arab league for many reasons, such as geographic proximity, ease of travel, proximity of time zones, convenient calendar arrangements, and shared sponsoring pharmaceutical companies. Over the years, and since its establishment, ArLAR has conducted 14 biannual congresses, with the last one being held in Kuwait in March 2023. The ArLAR activities are organized and managed by dedicated scientific and media committees. The vision of ArLAR is to be an internationally recognized professional league for rheumatology. One of its main missions is to enhance education and research among Arab countries and to build formal bridges between Arab rheumatologists and international rheumatology communities. ArLAR comprises a board of directors, an executive committee, a scientific committee, a general assembly, a media committee, and eight special interest groups. The board aims to maintain continuous collaboration among the committees and offer opportunities to engage medical staff and the public in ArLAR activities. The league has well-constructed bylaws, formed in 2019 and written in Arabic, the official language of the league. The bylaws were updated again in 2023.

  • The rheumatology workforce in the Arab countries: current status, challenges, opportunities, and future needs from an ArLAR cross-sectional survey

    by Nelly Ziade, Ihsane Hmamouchi, Chafika Haouichat, Fatemah Baron, Sulaiman Al Mayouf, Nizar Abdulateef, Basel Masri, Manal El Rakawi, Lina El Kibbi, Manal El Mashaleh, et al.

    The Arab League of Associations for Rheumatology (ArLAR) Research Group (ARCH) conducted this study to investigate the number of current practicing rheumatologists in the Arab countries, to estimate the projected number of rheumatologists in 10 years, and to evaluate the current workload, practice profile, consultation waiting time, and geographical mobilities of these rheumatologists. This cross-sectional survey study was conducted in 16 Arab countries in two parts. The first survey was addressed nominally to national societies to estimate the current and projected workforce. The second was an anonymous e-survey elaborated by the study steering committee on the Google Forms platform and distributed to Arab rheumatologists using social media, WhatsApp, and mass e-mails to evaluate their practice. The mean number of rheumatologists in Arab countries was 0.84 per 100,000 inhabitants (mean age 47.5 years, 55% females), ranging from 0.06 (Sudan) to 1.86 (Tunisia). The number of rheumatologists is expected to increase by 50% in 2032. Nevertheless, a 20% increase in population associated with an increase in demand is also expected. Data from 446 rheumatologists (mean age 43.9 years, 60.5% females) revealed that 72% worked full-time, and 53% were employed in the public sector only. The average waiting time for a rheumatology consultation was 19.9 days. Of 394 rheumatologists, 19% obtained their rheumatology diplomas from non-Arab countries, and 47% of Gulf rheumatologists were non-citizen physicians. Considering local demographic disparities, healthcare system differences, and geographical mobilities, national authorities are advised to implement effective intervention plans to optimize the rheumatology workforce.


  • Rheumatologic Aspects of the COVID-19 Pandemic: A Practical Resource for Physicians in Kuwait and the Gulf region as Recommended by the Kuwait Association of Rheumatology

    by Fatemah Baron, Heba Alhajeri, Fatemah Abutiban, Mona Almutairi, Adel Alawadhi, Ali Aldei, Adeeba Alherz, Yaser Ali, Saud Alsayegh, Ahmed Dehrab, et al.

    : The Kuwait Association of Rheumatology members met thrice in April 2020 to quickly address and support local practitioners treating rheumatic disease in Kuwait and the Gulf region during the coronavirus disease 2019 (COVID-19) pandemic. Because patients with rheumatic and musculoskeletal disease (RMD) may need treatment modifications during the COVID-19 pandemic, we voted online for the general guidance needed by local practitioners. In this review, we have addressed patients' vulnerability with rheumatic disease and issues associated with their optimum management. Our recommendations were based on the formulation of national/international guidelines and expert consensus among KAR members in the context of the Kuwaiti healthcare system for patients with RMD. The most recent reports from the World Health Organization, the Center for Disease Control, the National Institutes of Health-National Medical Library, and the COVID-19 educational website of the United Kingdom National Health Service have been incorporated. We discuss the management of RMD in various clinical scenarios: screening protocols in an infusion clinic, medication protocols for stable patients, and care for patients with suspected or confirmed COVID infection and whether they are stable, in a disease flare or newly diagnosed. Further, we outline the conditions for the hospital admission. This guidance is for the specialist and non-specialist readership and should be considered interim as the virus is relatively new, and we rely on the experience and necessity more than evidence collection. The guidance presented should be supplemented with recent scientific evidence wherever applicable.